Agios Pharmaceuticals announces anticipated 2024 milestones

Agios expects to execute on the following additional key milestones and priorities by the end of 2024: Thalassemia: Two key milestones for the year, including reporting topline data from the Phase 3 ENERGIZE-T study of mitapivat in transfusion-dependent thalassemia and filing for FDA approval of mitapivat in thalassemia year-end. Sickle Cell Disease: Complete enrollment in the Phase 3 portion of the RISE UP study of mitapivat year-end. Pediatric PK Deficiency: Complete enrollment in the Phase 3 ACTIVATE-kids study of mitapivat mid-year. Report topline data from Phase 3 ACTIVATE kids-T study now mid-year. Lower-risk Myelodysplastic Syndromes: Dose first patient in Phase 2b study of AG-946 mid-year. Other: Potential approval of Servier’s vorasidenib for the treatment of IDH-mutant diffuse glioma. The FDA has assigned a PDUFA action date of August 20, 2024. Agios retains certain economic rights, as described above.